| MEDIVATION-INC |
MEDIVATION-INC |
80%
|
He was the initial financier and an independent director of Medivation, Inc. (MDVN: Nasdaq), from 2005 to December 2012 |
| BOKO-THERAPEUTICS |
BOKO-THERAPEUTICS |
75%
|
Ian is also a member of the board of directors of BoKo Therapeutics |
| ENZO-BIOCHEM-INC |
ENZO-BIOCHEM-INC |
75%
|
Ian is also a member of the board of directors of Enzo Biochem, Inc., a Nasdaq listed company |
| INTENSITY-THERAPEUTICS-INC |
INTENSITY-THERAPEUTICS-INC |
75%
|
Ian is also a part-time consultant to Intensity Therapeutics, Inc. |
| INTS |
Intensity Therapeutics, Inc. |
72%
|
Reciprocal relationship from INTS graph: Reciprocal relationship from ATON graph: Reciprocal relationship from INTS graph: Reciprocal relationship from ATON graph: Reciprocal relationship from INTS g… |
| INTS |
Intensity Therapeutics, Inc. |
72%
|
on originally in OCI during the fiscal year. 33 Results of Operations for Fiscal 2024 Compared to Fiscal 2023 We incurred a net loss of approximately $75.4 million during Fiscal 2024, which includes … |
| JNJ |
Johnson & Johnson |
72%
|
Reciprocal relationship from JNJ graph: Reciprocal relationship from ATON graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from ATON graph: ity of California, Santa Barbara. Rob… |
| JNJ |
Johnson & Johnson |
72%
|
ity of California, Santa Barbara. Robert Kramer, PhD has served as our Chief Scientific Officer since January 2019 . Dr. Kramer has over 33 years of experience in the pharmaceutical industry and is t… |
| ARCTOSE-STRATEGY-LLC |
ARCTOSE-STRATEGY-LLC |
62%
|
ity of California, Santa Barbara. Robert Kramer, PhD has served as our Chief Scientific Officer since January 2019 . Dr. Kramer has over 33 years of experience in the pharmaceutical industry and is t… |
| ARCTOS-STRATEGY-LLC |
ARCTOS-STRATEGY-LLC |
62%
|
ity of California, Santa Barbara. Robert Kramer, PhD has served as our Chief Scientific Officer since January 2019 . Dr. Kramer has over 33 years of experience in the pharmaceutical industry and is t… |
| BONTAN-CORPORATION-INC |
BONTAN-CORPORATION-INC |
62%
|
d and continues to enact significant new tariffs, and President Trump has directed various federal agencies to further evaluate key aspects of U.S. trade policy. There has been and are ongoing discus… |
| CO-LLC |
CO-LLC |
62%
|
preservation policy referenced in that rule. 35 Results of Operations for Fiscal 2024 Compared to Fiscal 2023 We incurred a net loss of approximately $75.4 million during Fiscal 2024, which includes … |
| COMPEDICA-HOLDINGS-LIMITED |
COMPEDICA-HOLDINGS-LIMITED |
62%
|
t presently utilize any quantitative measures to monitor its capital. There have been no changes to the Company’s approach to capital management during the years ended March 31, 2025 and 2024. F- 41 … |
| CULLINAN-ONCOLOGY-INC |
CULLINAN-ONCOLOGY-INC |
62%
|
holders of the Series B Warrants, Series C Warrants and Placement Agent Warrants will be entitled to receive cash consideration in an amount equal to the Black-Scholes value of the Series B Warrants,… |
| IFRS-DISCUSSION-GROUP |
IFRS-DISCUSSION-GROUP |
62%
|
. The CEO of Portage previously served as a part-time officer of Intensity until becoming a consultant in 2023. Additionally, Intensity provided services (primarily rent) to Portage through April 202… |
| IMMUNOVA-LLC |
IMMUNOVA-LLC |
62%
|
leased properties. ITEM 4A – UNRESOLVED STAFF COMMENTS None. 30 ITEM 5 – OPERATING AND FINANCIAL REVIEW AND PROSPECTS (A) OPERATING RESULTS (All Amounts in 000’$) The following discussion should be r… |
| IRL-LIMITED |
IRL-LIMITED |
62%
|
new financing transactions. The following description assumes the availability of additional capital to support ongoing and future clinical development. 32 Results of Operations for Fiscal 2025 Compa… |
| NUVATION-BIO-SHATTUCK-LABS-ARCUS-BIOSCIENCES-SYN |
NUVATION-BIO-SHATTUCK-LABS-ARCUS-BIOSCIENCES-SYN |
62%
|
holders of the Series B Warrants, Series C Warrants and Placement Agent Warrants will be entitled to receive cash consideration in an amount equal to the Black-Scholes value of the Series B Warrants,… |
| PORTAGE-BIOTECH-INC |
PORTAGE-BIOTECH-INC |
62%
|
d and continues to enact significant new tariffs, and President Trump has directed various federal agencies to further evaluate key aspects of U.S. trade policy. There has been and are ongoing discus… |
| PORTAGE-MERGER-SUB-I-INC |
PORTAGE-MERGER-SUB-I-INC |
62%
|
d and continues to enact significant new tariffs, and President Trump has directed various federal agencies to further evaluate key aspects of U.S. trade policy. There has been and are ongoing discus… |
| PORTAGE-PHARMA-LTD |
PORTAGE-PHARMA-LTD |
62%
|
d and continues to enact significant new tariffs, and President Trump has directed various federal agencies to further evaluate key aspects of U.S. trade policy. There has been and are ongoing discus… |
| SALVARX-GROUP |
SALVARX-GROUP |
62%
|
5, 2022. Includes 14,600 vested stock options to purchase ordinary shares granted March 30, 2023. (7) Includes 30,000 vested stock options to purchase ordinary shares and excludes 30,000 unvested sto… |
| SALVARX-LIMITED |
SALVARX-LIMITED |
62%
|
d and continues to enact significant new tariffs, and President Trump has directed various federal agencies to further evaluate key aspects of U.S. trade policy. There has been and are ongoing discus… |
| SALVARX-LLC |
SALVARX-LLC |
62%
|
cussion. The Company’s 44 % interest in Stimunity was transferred from Portage to iOx in December 2023 and was increased to 48.9 % upon the conversion of the convertible note to equity; (c) Saugatuck… |
| SAUGATUCK-RX-LLC |
SAUGATUCK-RX-LLC |
62%
|
holders of the Series B Warrants, Series C Warrants and Placement Agent Warrants will be entitled to receive cash consideration in an amount equal to the Black-Scholes value of the Series B Warrants,… |
| SAUGATUCK-THERAPEUTICS-LTD |
SAUGATUCK-THERAPEUTICS-LTD |
62%
|
holders of the Series B Warrants, Series C Warrants and Placement Agent Warrants will be entitled to receive cash consideration in an amount equal to the Black-Scholes value of the Series B Warrants,… |
| TARUS-THERAPEUTICS-LLC |
TARUS-THERAPEUTICS-LLC |
62%
|
holders of the Series B Warrants, Series C Warrants and Placement Agent Warrants will be entitled to receive cash consideration in an amount equal to the Black-Scholes value of the Series B Warrants,… |
| THERAPEUTICS-LTD |
THERAPEUTICS-LTD |
62%
|
leased properties. ITEM 4A – UNRESOLVED STAFF COMMENTS None. 30 ITEM 5 – OPERATING AND FINANCIAL REVIEW AND PROSPECTS (A) OPERATING RESULTS (All Amounts in 000’$) The following discussion should be r… |
